Altria Group: Focus on Oral Tobacco Products and Growth

Dec.01.2022
Altria Group: Focus on Oral Tobacco Products and Growth
Altria Group's focus on oral tobacco products leads to expected growth in adjusted earnings per share by 4.5-6%.

US tobacco company Altria Group, Inc. (MO) appears well-prepared to tackle rising costs and weak cigarette sales by focusing on oral tobacco products, thanks to its strong pricing power. The company is expecting adjusted earnings per share between $4.81 and $4.89 in 2022, a growth of 4.5-6% compared to $4.61 in 2021.


Let's delve deeper and take a closer look.


Factors supporting Altria


Due to the serious health risks associated with smoking, consumers are turning to products with reduced risk or no smoke. Altria has been adapting to the changing market by offering a variety of oral, electronic, and heated tobacco products. Altria, through its subsidiary Helix Innovations, owns on!, a popular tobacco-derived nicotine (TDN) pouch product. Management believes that on! is worth mentioning as part of Altria's smoke-free product portfolio as oral TDN products are becoming more popular in the US due to their low-risk claims. In the third quarter of 2022, the net revenue of the oral tobacco products segment increased by 7% compared to the same period last year to $665 million due to price increases. The domestic shipment volume of this segment increased by 1.3%, mainly due to changes in trade inventory, industry growth rate, and calendar differences, with reported shipping volume soaring by about 70%. Additionally, the retail market share of oral tobacco increased compared to the previous quarter, reaching 5.2 share points in the third quarter.


Altria Group surprises with price, consensus, and earnings per share.


Tobacco giant Altria has remained strong thanks to its powerful pricing ability, even during periods of weak cigarette shipments and increased taxes. While higher prices may lead to decreased cigarette consumption, it appears that due to the addictive nature of cigarettes, smokers are willing to accept price hikes. In Q3 of 2022, higher pricing supported revenue in Altria's smokeable and oral tobacco product segments. Additionally, higher pricing helped the adjusted operating company income for both segments. This trend may continue to have room for growth.


Barrier or obstacle.


Cost inflation and rising natural gas prices were unfavorable factors in the third quarter. Additionally, wage costs increased. The continued presence of these factors remains a concern. Management's outlook for 2022 takes into account planned investments related to costs aimed at improving the digital consumer engagement system, strengthening research, development, and regulatory readiness costs for smokeless products, and supporting marketing activities for the company's smokeless products. The outlook also includes expectations for inflation in settlement agreement costs, as well as direct and indirect material costs. In the third quarter of 2022, Altria's net income decreased by 3.5% year-on-year to $6.55 billion, due to lower revenue from the wine segment divestment in October 2021 and decreased revenue from the combustible products segment. Excluding excise taxes, revenue decreased by 2.2% to $5.412 billion.


In the field of smoking products, net income decreased by 1.6% year-on-year to $5.882 billion due to decreased shipments and increased promotional investments. Domestic cigarette shipments fell by 9.2% year-on-year, primarily driven by industry decline and losses in retail market share. However, changes in trade inventory partially offset this impact. After adjusting for changes in trade inventory and other factors, estimates indicate that domestic cigarette shipments for smoking products decreased by 8%.


Bottom line


Overall, cigarette sales have been impacted by increased consumer health awareness and regulatory barriers. However, according to a third quarter earnings call with management, research suggests that despite price increases in the tobacco category compared to other categories, tobacco consumers are more likely to continue purchasing their preferred brands. Pricing power and advantages with smokeless tobacco products may keep Altria on a growth trajectory. The stock price of this third-ranked (hold) Zacks company has risen 1.5% over the past three months, compared to the industry's 1% increase.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Swedish Politicians Ask European Commission to Clarify Legality of France’s Nicotine Pouch Ban
Swedish Politicians Ask European Commission to Clarify Legality of France’s Nicotine Pouch Ban
France’s ban on oral nicotine pouches has triggered an immediate response in Sweden. Swedish Minister for Foreign Trade Benjamin Dousa said Sweden had mobilized strongly against the ban and argued that it constitutes a clear obstacle to the free movement of goods within the EU single market. Swedish officials say the measure affects a strategically important domestic industry and conflicts with Sweden’s harm-reduction approach to public health.
Apr.14 by 2FIRSTS.ai
Cross-Party Romanian Lawmakers Propose Ban on E-Cigarettes and Heated Tobacco Use in All Enclosed Public Spaces
Cross-Party Romanian Lawmakers Propose Ban on E-Cigarettes and Heated Tobacco Use in All Enclosed Public Spaces
Lawmakers from Romania’s USR, PSD and PNL have submitted a bill that would ban e-cigarettes, vapes and heated tobacco devices in all enclosed public spaces. The proposal would redefine “smoking” so that inhaling aerosols produced by heating or vaporizing products containing tobacco, nicotine or other substances intended for inhalation would also be considered smoking, except for medical-use products.
Apr.17 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Nearly 35.00% of Surveyed Retailers Shifted to Online Sales After Tighter Controls in Vietnam
Nearly 35.00% of Surveyed Retailers Shifted to Online Sales After Tighter Controls in Vietnam
A study of nearly 2,500 university students in Hanoi, Da Nang, Hue, and Ho Chi Minh City found that the average age of first use of e-cigarettes and heated tobacco products was 16.90. The findings were presented on April 9 in Hanoi. The study also found that 14.00% of students had tried e-cigarettes and 3.00% were current users, while the figures for heated tobacco were 6.00% and 0.80%. % of surveyed retail outlets moving to online sales.
Apr.10 by 2FIRSTS.ai
Spain’s Nicotine Pouch Sales Reached 5 Million Cans in 2025, Industry Says 2026 Could Hit 8 Million
Spain’s Nicotine Pouch Sales Reached 5 Million Cans in 2025, Industry Says 2026 Could Hit 8 Million
Spain’s Nicotine Pouch Association said nicotine pouch sales in Spain reached 5 million cans of 20 units in 2025 and are expected to rise 60% to 8 million in 2026. The group said there are currently 20 to 30 brands on the Spanish market and called for regulation proportionate to product risk. It also opposed a proposal to reduce nicotine content to 0.99 mg per pouch, saying it would amount to a de facto ban on the category.
Mar.19 by 2FIRSTS.ai
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
Sesh said its Premarket Tobacco Product Application (PMTA) for 64 nicotine pouch SKUs has been accepted by the U.S. Food and Drug Administration (FDA) and advanced to the Filing stage, entering substantive scientific review. Industry experts say the development signals that the application has crossed a key technical and regulatory threshold, while also highlighting growing divergence in regulatory capability and market positioning within the nicotine pouch category.
Special Report
Mar.24 by 2FIRSTS.ai